LP
ENGNW icon

LMR Partners’s enGene Therapeutics Warrants ENGNW Stock Holding History

LMR Partners’s Portfolio ENGNW Stock Details ENGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$811K Buy
320,687
+241,160
+303% +$715K ﹤0.01% 1017
2025
Q4 		$235K Buy
+79,527
New +$182K ﹤0.01% 1255

Other funds holding ENGNW

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

LMR Partners's ENGNW Position: Q1 2026 in Review

LMR Partners increased its enGene Therapeutics Warrants (ENGNW) stake by 303% in Q1 2026, buying an estimated $715K and bringing the position to 320,687 shares worth $811K. The position accounts for ﹤0.01% of the portfolio, ranked #1017.

LMR Partners first reported a position in ENGNW in Q4 2025 and has held it in 2 quarters since. 11 funds tracked by Wall St. Rank hold ENGNW as of Q1 2026.

  • LMR Partners held 320,687 shares of enGene Therapeutics Warrants worth $811K as of Q1 2026.
  • LMR Partners bought 241,160 enGene Therapeutics Warrants shares in Q1 2026, an estimated $715K.
  • enGene Therapeutics Warrants made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #1017 holding.
  • LMR Partners first reported a position in enGene Therapeutics Warrants in Q4 2025 and has held it in 2 quarters since.
  • 11 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.